Cream for mild to moderate hidradenitis suppurativa
Part of Infections, Skin clinical trials.
This trial tests a new cream (EVO101) for people with mild to moderate hidradenitis suppurativa (HS), a skin condition causing painful lumps. It aims to see if the cream can reduce the number of lesions. Participants cannot use certain other HS treatments during the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had hidradenitis suppurativa for at least 3 months.
- Your HS is mild to moderate (not severe or very mild).
- You have at least 5 active lesions (lumps, abscesses, or tunnels) at the start.
- You agree not to use other HS treatments (like antibiotics or certain washes) during the study.
- If you could become pregnant, you agree to use highly effective birth control or abstain from sex.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.
This trial is testing an experimental tablet called LT-002-158 in adults with moderate to severe hidradenitis suppurativa (HS) that hasn't improved enough with standard treatments. The goal is to see if it's safe and helps reduce painful lumps and abscesses.
This trial tests a new medication called CIT-013 for people with moderate to severe hidradenitis suppurativa (HS) who have not had enough relief from oral antibiotics. The goal is to see if this treatment can reduce painful bumps and abscesses.
This trial tests an investigational medicine, SPY072, for adults with moderate to severe hidradenitis suppurativa (also known as HS), a skin condition that causes painful lumps and sores. If you join, you'll help see if this treatment is safe and effective.
This trial tests a new drug called NAV-240 for people with hidradenitis suppurativa (HS) who have not had success with antibiotics. The goal is to see if the drug can reduce the number of painful lumps and improve symptoms.
This trial tests a 1726-nm laser to reduce inflamed nodules in people with mild to moderate hidradenitis suppurativa (HS). It compares treated and untreated areas to see if the laser helps without affecting the rest of the body.
Hear when a new Hidradenitis Suppurativa (HS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.